Dmitry Valentinovich Demchenko

Dmitry Valentinovich Demchenko

Auto-generated profile, based on publicly available information

Dmitry Valentinovich Demchenko

ЗАО «Санкт-Петербургский институт фармации

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2010 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
ASAlexander B. Schikov
Alexander B. Schikov
OPOlga N. Pozharitskaya
Olga N. Pozharitskaya
VMValery G. Makarov
Valery G. Makarov
DDDmitry V. Demchenko
Dmitry V. Demchenko
ESEvgenia Shikh
Evgenia Shikh

20 March 2007 in Journal of Separation Science
Verified
Journal Article
Closed access
PDF file
OPOlga N. Pozharitskaya
Olga N. Pozharitskaya
VKVera M. Kosman
Vera M. Kosman
ASAlexander B. Schikov
Alexander B. Schikov
DDDmitry V. Demchenko
Dmitry V. Demchenko
AEAnna Yu. Eschenko
Anna Yu. Eschenko
VMValery G. Makarov
Valery G. Makarov

1 November 2012 in Russian Journal of Marine Biology
Verified
Journal Article
Closed access
PDF file
ASAlexander Shikov
Alexander Shikov
OPOlga N. Pozharitskaya
Olga N. Pozharitskaya
DDD. V. Demchenko
D. V. Demchenko
ASAlexander B. Schikov
Alexander B. Schikov
VMV. G. Makarov
V. G. Makarov
Fish, like other aquatic organisms, are a potential source of structurally diverse bioactive compounds. Studies of the pharmacological effects of fish peptides have revealed their antihypertensive,...

1 December 2011 in JPC – Journal of Planar Chromatography – Modern TLC
Verified
Journal Article
Closed access
DDDmitry Demchenko
Dmitry Demchenko
OPOlga N. Pozharitskaya
Olga N. Pozharitskaya
ASAlexander B. Schikov
Alexander B. Schikov
VMValery Makarov
Valery Makarov

16 January 2014 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
DDD. V. Demchenko
D. V. Demchenko
OPOlga N. Pozharitskaya
Olga N. Pozharitskaya
ASAlexander B. Schikov
Alexander B. Schikov
EFE. V. Flisyuk
E. V. Flisyuk
ARA. V. Rusak
A. V. Rusak
VMV. G. Makarov
V. G. Makarov

26 November 2020 in Drug development & registration
Verified
Journal Article
Open access
PDF file
DDD. V. Demchenko
D. V. Demchenko
Е(Е. А. Джайн (Корсакова)
Е. А. Джайн (Корсакова)
VBV. Yu. Balabanyan
V. Yu. Balabanyan
MMM. N. Makarova
M. N. Makarova
VMV. G. Makarov
V. G. Makarov
ВБВ. Ю. Балабаньян
В. Ю. Балабаньян
Introduction. 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil is a substance of scientific interest intended for the treatment of HIV-infection. However, its low bioavailability is a major limitation in successful drug delivery by oral route. Therefore, the objective of the present work was to enhance itssolubility by using solid dispersion technique followed by the development of a solid dosage form.Aim. Development of the composition and technology of tablets based on 1- [2-(2-benzoylphenoxy)ethyl]-6-methyluracil with the appropriate technological properties providing the most complete release of the active pharmaceutical ingredient (API) in vitro.Materials and methods. The pharmaceutical substance 1-[2-(2-benzoylphenoxy) ethyl]-6-methyluracil is a crystalline powder with poor solubility. Solid dispersions were prepared using Lactose, Kollidon® 17PF, Kollidon® 30, Kollidon® VA64, Kollidon 90F, and PEG-6000 as a carrier mostly in 1:4 ratio by two methods – co-melting and solvent evaporation. The technological properties of substance, tablet masses and tablet quality were determined according to the methods described in the State Pharmacopoeia of the Russian Federation (14th edition).Results and discussion. Article shows the results of development of the composition and technology of a medicine in the form of tablets based on the substance 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil. Solid dispersion technique was used to improve the biopharmaceutical properties of 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil.Conclusion. In vitro dissolution studies showed enhanced dissolution rate of the drug-loaded solid dispersion with Kollidon 17PF as a carrier as compared to pure drug.